These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23873362)

  • 1. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
    Lasseter KC; Sologuren A; La Noce A; Dilzer SC
    Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
    Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
    Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.
    Togawa M; Yamaya H; Rodríguez M; Nagashima H
    Clin Drug Investig; 2016 Dec; 36(12):1011-1021. PubMed ID: 27498100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study.
    Sádaba B; Azanza JR; García-Bea A; Labeaga L; Campo C; Valiente R
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):265-272. PubMed ID: 31820304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
    Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
    Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
    Tayo B; Taylor L; Sahebkar F; Morrison G
    Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation.
    Ochoa D; Román M; Belmonte C; Martín-Vilchez S; Mejía-Abril G; Abad-Santos F; Hernández G; Arranz P; Elgezabal L; Fernández N
    Adv Ther; 2021 Jul; 38(7):4070-4081. PubMed ID: 34125400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
    Noveck RJ; Preston RA; Swan SK
    Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
    Stangier J; Rathgen K; Stähle H; Mazur D
    Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
    Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.
    Farré M; Pérez-Mañá C; Papaseit E; Menoyo E; Pérez M; Martin S; Bullich S; Rojas S; Herance JR; Trampal C; Labeaga L; Valiente R
    Br J Clin Pharmacol; 2014 Nov; 78(5):970-80. PubMed ID: 24833043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
    Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
    Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral availability of bilastine.
    Sádaba B; Gómez-Guiu A; Azanza JR; Ortega I; Valiente R
    Clin Drug Investig; 2013 May; 33(5):375-81. PubMed ID: 23529786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilastine: a new H
    Church MK; Labeaga L
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment.
    Joukhadar C; Herranz U; Pernerstorfer T; Assandri A; Klein N; Schrolnberger C; Lackner E; Eichler HG; Müller M
    Eur J Clin Pharmacol; 2001 Mar; 56(12):905-10. PubMed ID: 11317479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
    Mahmood I
    Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
    Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
    Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.